INTERFERON ALFA-2B
CD19+ Acute Leukemia
SWOG Cancer Research Networkprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the CD19+ Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dasatinib SWOG Cancer Research Network | Phase 2/3 | B |
Patient Derived Cd19 Specific Car T Cells Also Expressing An Egfrt Seattle Children's Hospital | Phase 1/2 | CCC |
Same molecule, other indications
INTERFERON ALFA-2B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →